Call for Abstract
9th International Conference on Leukemia and Hematologic Oncology, will be organized around the theme “Exploring latest Innovations and Interactive discussions on Leukemia and Hematologic Oncology care.”
Hematologic Oncology 2017 is comprised of 16 tracks and 68 sessions designed to offer comprehensive sessions that address current issues in Hematologic Oncology 2017.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Leukaemia is a malignancy (cancer) of blood cells. In leukemia, abnormal blood cells are produced in the bone marrow. Leukemia involves the production of abnormal white blood cells the cells responsible for struggling infection. The abnormal cells in leukemia not function in the same way as normal white blood cells. The leukemia cells continue to develop and divide, finally crowding out the normal blood cells. The end result is that it becomes tough for the body to fight infections, control haemorrhage, and carriage oxygen.
- Track 1-1Acute Myelogenous Leukemia (AML)
- Track 1-2Acute Lymphocytic Leukemia (ALL)
- Track 1-3Chronic Myelogenous Leukemia (CML)
- Track 1-4Chronic Lymphocytic Leukemia (CLL)
- Track 1-5Advanced treatment for Myelodysplastic Syndrome
- Track 1-6Blood components
Erythrocytes are also known as red blood cells which carry oxygen to the body and collect carbon dioxide from the body by the use of haemoglobin and its life span of 120 days. along the side the leucocytes helps in protecting the healthy cells because the W.B.C (leucocytes) act as the defending cells in protecting the immune system from the foreign cells. Formation of blood cellular components are called as Hematopoiesis and all the cellular blood components are derived from hematopoiesis stem cells in a healthy individual nearly 1011–1012 new blood cells are produced these help in steady peripheral circulation. If there is a increases of R.B.C in the body these causes polycythemia these can be measured through haematocrit level.
- Track 2-1Blood components
- Track 2-2Erythrocytes and Leukocytes
- Track 2-3Platelets and Thrombocytopenia
- Track 2-4Hemoglobin and Blood Plasma
- Track 2-5Complete Blood Count and Polycythemia
- Track 2-6Polymorphism and Haematopoiesis
Hematologic Oncology is the branch of medicine concerned with the study, diagnosis, treatment, and prevention of diseases related to blood. Haematology includes the study of etiologist involves treating diseases that affect the production of blood and its components, such as blood cells, haemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. The laboratory work that goes into the study of blood is frequently performed by a medical technologist or medical laboratory scientist. Haematologists also conduct studies in oncology and work with oncologists, people who may specialize only in that field instead of both-the medical treatment of cancer. There are various disorders that people are affected by haematology. A few of these different types of blood conditions that are looked at include anemia, haemophilia, general blood clots, bleeding disorders, etc. As for related blood cancers such as leukemia, myeloma, and lymphoma, these are more serious cases that need to be diagnosed
- Track 3-1Myeloma
- Track 3-2Myelodysplastic syndromes
- Track 3-3Multiple Myeloma
- Track 3-4Leukaemia
- Track 3-5Lymphoma
- Track 3-6Targeted Therapy
Pediatric Hematology is a branch of Hematology which deals with the treatment and care of child or teen having Blood Disorder. A paediatric haematologist has the qualifications and experience to evaluate and treat child or teen with Hematologic Disorders. The caring nature to deal with children or teens with blood diseases and blood cancersis learned from progressive training and experience in practice. Pediatric hematologists treat children and teens from birth through young adulthood. Children and teens with blood disorders need special attention than adults. Their bodies are growing and have distinctive medical needs. They normally express their concerns in a different way than adults do. They are not always able to be easy-going and cooperative. Pediatric hematologists know how to examine and treat them in a way to makes them relaxed and cooperative. Even most pediatric hematologists offices are arranged and decorated according to children and teens in mind.
Hematology nurses are especially skilled to provide nursing care for patients with blood diseases or disorders. They may also assist with blood transfusions, blood tests, research, and chemotherapy. If you go into hematology, expect to have more obligation than other nurses, prescriptive expert, and the ability to order diagnostic lab work. Some of the additional commonly-known blood diseases and disorders such as: leukemia, lymphoma, sickle cell anaemia and haemophilia are encounter by hematology nurses. Hematology nurses initiate a plan of care to manage symptoms that result from such blood problems. Hematology nursing is often thoroughly associated with oncology nursing, and some nurses will help patients with pain supervision if their cancer is particularly aggressive. Hematology nurses may work with adults only or specialize in working only with children i.e. Pediatric Hematology nurses. Their responsibilities include: taking medical antiquities, performing examinations, starting IVs and working with physicians to diagnose various blood diseases and disorders. Hematology nurses also educate patients and their families on how to live with and manage their blood disease. They may also assist with blood transfusions, blood tests, research and chemotherapy. Advanced practice hematology nursing have some prescriptive authority and can also order diagnostic lab work done
The global Hematology diagnostics and drugs market is likely to expand from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a five-year compound annual growth rate (CAGR) of 7.5%. A Blood disorder, the chief segment is anticipated to reach nearly $57.3 billion and $80 billion in 2015 and 2020, respectively, representing five-year CAGR of 6.9%. Hematological oncology is the fastest-growing segment, should raise almost $24 billion in 2015 to $38.2 billion in 2020 at a five-year CAGR of 9.7%. Reagents and diagnostics as a segment should reach $6.1 billion in 2020 at a five-year CAGR of 3.2%.The Americas controlled the largest share of 41.75% of the worldwide Hematology market at a predicted $1,810.4 million in 2013, anticipated to reach $2,479.05 million by 2018, at a CAGR of 6% from 2013 to 2018. Europe holds the second largest Hematology market share. Germany precise the largest share almost 20% of the European market at an anticipated $272.8 million in 2013, and is estimated to grasp $349.7 million by 2018, at a CAGR of 5.4% from 2013 to 2018. The Asia and Middle East Hematology market is growing in double digits and will remain to grow in the upcoming years. China controlled the major share of almost 53% of the Asian Hematology market at a predictable $216.0 million in 2013, estimated and is to grasp $429.1 million by 2018, at a CAGR of 15.4% from 2013 to 2018.
Blood tests are done on animals for a variety of reasons. Screening tests, such as a complete blood count (CBC), may be done on clinically normal animals when they are acquired to avoid a financial and/or emotional commitment to a diseased animal, to examine geriatric patients for subclinical disease, or to identify a condition that might make an animal an anesthetic or surgical risk. Screening tests are often done when an ill animal is first examined, especially if systemic signs of illness are present and a specific diagnosis is not apparent from the history and physical examination. Tests may be done to assist in the determination of the severity of a disease, to help formulate a prognosis, and to monitor the response to therapy or progression of disease. Decisions to request hematology testsin animals are mainly based on the cost of the test versus the possible benefit of the result to the animal. A CBC is routinely done to establish a database for patient evaluation, while other hematology tests may be done in an attempt to evaluate a specific problem.
Anemia is the most common type of blood disorder we treat. Patients with anemia have a deficiency of oxygen-rich red blood cells or their red blood cells do not function properly. A low level of hemoglobin, the iron-rich protein that carries the oxygen in red blood cells, signals the condition. Anemia can be chronic, or a temporary condition caused by other health issues, including cancer treatment, hepatitis C, and HIV/AIDS. Anemia frequently remains undiagnosed because it is an underlying condition of other health issues, including cancer, cardiovascular disease, diabetes, HIV/AIDS, inflammatory bowel disease, chronic kidney disease, and rheumatoid arthritis. Hemophilia is a rare, typically inherited blood disorder in which the blood does not properly clot and causes excessive bleeding, which can cause damage to organs, joints, and tissues. Patient may suffer excessive bleeding from the site of an injury or from internal bleeding. Clotting Disorders Hematologists also treat conditions related to the proteins that trigger bleeding and clotting, including thrombosis (clotting) and hemostasis (bleeding). Thrombosis refers to the formation of abnormal blood clots that become embedded in a major vein or artery, blocking blood circulation. Blood clots can cause pain, swelling, or warmth in the affected area, and can be life-threatening. Hemostasis is the process of controlling bleeding. Blood Cancers Cancerous blood conditions include leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.
- Track 8-1Hemophilia A, B and C
- Track 8-2Idiopathic Thrombocytopenic Purpura (ITP)
- Track 8-3Von Willebrand
- Track 8-4Bleeding Disorders & Platelet Function Defects
- Track 8-5Disease Associated with Coagulation Factors
- Track 8-6Hemoglobinopathies
- Track 8-7Biomarkers for Blood Cancers
- Track 8-8Molecular Pathogenesis and Personalized Treatment
- Track 8-9Genetic Blood Disorder
Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumor marker-based diagnostic tests.
- Track 9-1Immunotherapeutic Approaches
- Track 9-2Hematopoietic System
- Track 9-3Lymphotoxin
- Track 9-4Immune Tolerance and Deficiencies
- Track 9-5Immunotherapy
Blood groups are of ABO type and but at present the Rh blood grouping of 50 well defined antigens in which 5 are more important they are D,C,c,E and e and Rh factors are of Rh positive and Rh negative which refers to the D-antigen. These D-antigen helps in prevention of erythroblast fetalis lacking of Rh antigen it defined as negative and presences of Rh antigen in blood leads to positive these leads to rh incompatibility. The prevention treatment of diseases related to the blood is called as the Hematology. The hematologists conduct works on cancer to. The disorder of immune system leading to hypersensitivity is called as Clinical Immunology and the abnormal growth of an infection are known as Inflammation and the arise of an abnormal immune response to the body or an immune suppression are known as Auto immune disorder. The stem cell therapy is used to treat or prevent a disease or a condition mostly Bone marrow stem cell therapy is seen and recently umbilical cord therapy Stem cell transplantation strategies remains a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases.
- Track 10-1Blood Groups and Rh Incompatibility
- Track 10-2Hematology and Clinical Immunology
- Track 10-3Immunology of Blood Cancer
- Track 10-4Inflammatory/Autoimmune Diseases
- Track 10-5Bone Marrow Stem Cell Therapy
- Track 10-6Stem Cell Transplantation Strategies
Ayurvedic medicine is an ancient Indian system of medicine which began about 5,000 years ago. It is not just one treatment. It is a way of diagnosing illness and using a wide range of treatments and techniques. Herbal medicine uses plants, or mixtures of plant extracts, to treat illness and promote health. It aims to restore your body's ability to protect, regulate and heal itself. It is a whole body approach, so looks at your physical, mental and emotional well-being. It is sometimes called phytomedicine, phytotherapy or botanical medicine. Naturopathic doctors (NDs) believe that cancer arises from an imbalance that causes a systemic breakdown within the body. Homeopathy is based on the theory of treating like with like. So to treat an illness a homeopathic therapist (homeopath) uses tiny doses of a substance that in large doses would actually cause the symptoms of the illness.
- Track 11-1Ayurvedic treatment for cancer
- Track 11-2Naturpathy and cancer
- Track 11-3Cancer and herbal medicine
- Track 11-4Homeopathy and cancer
Hematologic malignancies are forms of cancer that begins in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are acute and chronic leukemia, lymphomas, multiple myeloma and myelodysplastic syndromes. Myeloproliferative neoplasms, or MPNs, are hematologic cancers that arise from malignant hematopoietic myeloid progenitor cells in the bone marrow, such as the precursor cells of red cells, platelets and granulocytes.Included in the MPN disease spectrum are essential thrombocythemia, polycythemia Vera and myelofibrosis . This scientific session will focus on all types of common or rare blood cancers such as acute promyelocytic leukemia (APL) and chronic myelomonocytic leukemia hairy cell leukemia (HCL), large granular lymphocytic leukemia (LGL), t-cell acute lymphoblastic leukemia (T-ALL), Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma Multiple myeloma, Childhood Leukemia and Myelodysplastic–Myeloproliferative diseases.
- Track 12-1Hairy Cell Leukaemia (HCL)
- Track 12-2T-cell Acute Lymphoblastic Leukemia (T-ALL)
- Track 12-3Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma
- Track 12-4Multiple Myeloma
- Track 12-5Childhood Leukemia
- Track 12-6Myelodysplastic–Myeloproliferative Diseases
- Track 12-7 Childhood Hematological Cancers
The estimate of how the disease will go for a patient is called prognosis. There are many factors affect prognosis that include: the type of cancer and where it is in the body, the stage of the cancer, the cancer’s grade. Grade provides clues about how quickly the cancer is likely to grow and spread certain traits of the cancer cells, the age and how healthy body was before cancer & how successful is the treatment.
- Track 13-1Rate of Metastasis
- Track 13-2Prognosis of Leukemia
- Track 13-3Lymphoma Prognosis
- Track 13-4Lymphoma Prognosis
- Track 13-5Myeloma Prognosis
- Track 13-6Myeloma Prognosis
Protein Biomarkers can be used as biomarkers for early detection of cancers especially used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis. The presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer. These will notice specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples.
- Track 14-1Biomarkers in cancer research
- Track 14-2Biomarkers in medicine
- Track 14-3Risk assessment, diagnosis
- Track 14-4Prognosis and treatment predictions
- Track 14-5Molecular cancer biomarkers
Bone Marrow Transplantation: A bone marrow transplant, also known as a haemopoietic stem cell transplant, replaces damaged bone marrow with healthy bone marrow stem cells. Bone marrow is a spongy tissue found in the hollow centres of some bones. It contains specialist stem cells, which produce the body's blood cells.
A biopsy is a sample of tissue taken from the body in order to examine it more closely. A doctor should recommend a biopsy when an initial test suggests that an area of tissue in the body isn't normal. Doctors may call that area of abnormal tissue a lesion, a tumour, or a mass.Topics of discussion in the scientific sessions are Bone Marrow Surgery, Stem Cell Surgery, Hematopoietic Cell Transplantations.
- Track 15-1Bone Marrow Surgery
- Track 15-2Stem Cell Transplantation Surgery
- Track 15-3Hematopoietic Cell Transplantations
An increasing number of diseases may be treated successfully by allogeneic bone marrow transplantation (BMT). Initially used for the treatment of immunodeficiency where a cell series or product is replaced, it has now become routine treatment for many forms of leukemia where the transplant provides the rescue after lethal marrow ablation. Recently, diseases such as thalassemia and other inherited metabolic diseases have also been treated by BMT. Formerly the problems of BMT were mainly concerned with graft versus host disease (GVHD) in HLA-matched transplants with HLA-mismatched ones not being possible as GVHD was usually fatal. Since the development of techniques for T cell removal the incidence of GVHD has greatly diminished. T cell removal has also allowed HLA haploidentical mismatched grafts to be performed successfully for immunodeficiency, but there is still a high graft rejection rate in leukemia.
- Track 16-1Development of Investigational New Drug
- Track 16-2Clinical Trials and ProceduresClinical Trials and Procedures
- Track 16-3Recent Products and Follow Ups
- Track 16-4Protocol Development
- Track 16-5Infusion Cell Therapy